The Canada contrast media market size was exhibited at USD 188.15 million in 2023 and is projected to hit around USD 384.19 million by 2033, growing at a CAGR of 7.4% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 202.07 Million |
Market Size by 2033 | USD 384.19 Million |
Growth Rate From 2024 to 2033 | CAGR of 7.4% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Modality, Product, Route of Administration, Application, End use |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Country scope | Canada |
Key Companies Profiled | Bayer AG; GE HealthCare; Guerbet; Lantheus Holdings, Inc. ; Bracco ; Voyageur Pharmaceuticals, Ltd; Grupo Juste |
Contrast media are agents used in medical imaging to enhance the visibility of internal body structures. They are crucial in diagnostic procedures such as X-rays, CT scans, MRIs, and ultrasounds. In Canada, the market for these substances is driven by increasing demand for advanced diagnostic imaging, the rising prevalence of chronic diseases, and a growing aging population.
According to the Canadian Cancer Society's 2024 report, researchers anticipated 88,100 cancer-related deaths and 247,100 new cancer cases in Canada for 2024. They projected that each day in 2024, approximately 675 Canadians would be diagnosed with cancer, and 241 Canadians would succumb to the disease. Technological advancements in imaging techniques and introducing novel contrast agents further propel the market. In addition, government initiatives aimed at improving healthcare infrastructure and accessibility contribute significantly to market expansion. With healthcare facilities increasingly adopting advanced imaging modalities, the demand for contrast media is set to rise steadily, ensuring robust market growth over the coming years.
Technological advancements play a pivotal role in the market growth. Developing new contrast agents that are more effective and safer for patients is a significant driver. For instance, the advent of microbubble contrast agents has enhanced ultrasound imaging, while gadolinium-based agents have improved MRI diagnostics. These innovations facilitate better image clarity and diagnostic accuracy, critical in early disease detection and treatment planning.
Furthermore, advancements in imaging technology, such as high-resolution and 3D imaging, require high-quality contrast media to achieve optimal results. For instance, in March 2024, Applied Pharmaceutical Innovation (API) and Voyageur Pharmaceuticals Ltd. entered into a Master Services Agreement (MSA). This collaboration is poised to significantly boost both organizations' dedication to innovation and bolster Canada's life sciences sector. The strategic partnership aims to expedite Voyageur's imaging contrast medium's development, production, and commercialization. Integrating artificial intelligence (AI) in imaging processes also supports advanced contrast media, enabling more precise and efficient diagnoses. As technology evolves, the Canadian market will likely see the introduction of even more sophisticated contrast agents, further driving market growth.
In addition, government initiatives and healthcare policies significantly impact the market in Canada. The Canadian government has been actively investing in the healthcare sector to enhance the quality and accessibility of medical services. Policies to reduce diagnostic wait times and improve patient outcomes directly influence the demand for advanced imaging modalities and contrast media. Programs such as the Canadian Institutes of Health Research (CIHR) funding and provincial healthcare funding initiatives support the adoption of cutting-edge medical technologies, including advanced contrast agents.
Furthermore, regulatory frameworks ensure the safety and efficacy of contrast media, promoting trust and widespread use among healthcare professionals. As the government continues prioritizing healthcare improvements and technological advancements, the market is expected to benefit from increased investment and supportive policies. For instance, in January 2023, Bayer AG announced that its iodine-based contrast agents, Ultravist-300 and Ultravist-370, were approved for contrast-enhanced mammography (CEM) in the European Union. Regulatory agencies worldwide are establishing guidelines to ensure Canada's contrast media therapies' safety, efficacy, and ethical use. Streamlined approval processes and clearer regulatory pathways encourage commercialization and market expansion investment, facilitating patient access to advanced treatment options.
The X-ray/Computed Tomography (CT) segment held the largest share of 64.36% in 2023. The increasing prevalence of chronic diseases, such as cancer and cardiovascular conditions, drives the demand for CT scans. CT imaging requires high-quality contrast agents to enhance image clarity and diagnostic accuracy.A study published by the National Library of Medicine in August 2022 revealed that over 5.4 million CT examinations were performed in Canada in 2019, with 50% utilizing contrast enhancement. The advent of safe radiopaque contrast agents for CT imaging has markedly improved the technique's effectiveness, enabling clear visualization of internal organ abnormalities and vascular structures. Contrast-enhanced CT imaging has become a crucial diagnostic tool for various medical decisions, particularly in emergency settings and high-resolution anatomical monitoring of cancer treatment. These advancements are projected to drive growth in the CT segment in the coming years.
The ultrasound segment is projected to grow the fastest during the forecast period. The swift introduction of ultrasound systems across Canada is expected to drive market growth in the near future.Industry stakeholders are joining forces to enhance the understanding of ultrasound contrast agents (UCAs). For instance, in April 2024, Northwest Imaging Forums (NWIF) and the International Contrast Ultrasound Society (ICUS) established an educational collaboration to oversee the administration of intravenous UCAs and conduct Contrast-Enhanced Ultrasound (CEUS) studies. The ICUS board includes healthcare professionals from Canada. The involvement of Canadian members in organizations dedicated to UCAs is expected to drive segment growth throughout the forecast period.
The Iodinated segment dominated the market with a share of 61.1% in 2023. CT procedures using intravenous iodinated contrast agents are extensively employed for diagnosing, treating, planning, and monitoring a wide range of diseases. Iodine-based contrast media enhance CT and X-ray images, providing better visualization of internal organs, the gastrointestinal tract, arteries, veins, soft tissues, and the brain. These contrast agents include various molecules such as iodixanol, iohexol, and iopamidol. The growing use of iodinated contrast media has led to shortages, prompting several authorities and organizations to focus on optimizing their use. For instance, in March 2023, the Canadian Agency for Drugs and Technologies in Health published a review identifying strategies to mitigate ICM shortages and strengthen the supply chain.
The microbubble segment is projected to grow at the fastest CAGR over the forecast period. The increasing approvals from Health Canada, the regulatory authority for microbubble contrast media products, are expected to propel segment growth in the upcoming years. For instance, in April 2024, Agitated Solutions, Incorporated obtained a Medical Device Establishment License (MDEL) from Health Canada for its innovative Orbis Microbubble Generator. The company's platform includes a contrast delivery and maneuver automation system alongside a proprietary ultrasound contrast agent (Orbis). Currently exclusive to Canada, the availability of these contrast agent products nationwide is anticipated to stimulate segment expansion throughout the forecast period.
The intravenous segment held the largest share of 48.9% in 2023 and is expected to grow at the fastest CAGR during the forecast period.Intravenous iodinated contrast media are crucial in CT scans and are widely used for disease assessment and treatment response evaluation. These contrast agents enhance tissue differentiation, accurately characterizing various lesions observed during the scan. Their significance is particularly notable in identifying lacerations affecting solid organs. The use of intravenous contrast media is essential and irreplaceable in most CT examinations focusing on the abdomen and pelvis. Furthermore, ultrasound contrast agents are injected intravenously to enhance the clarity and functionality of ultrasound images during CEUS examinations. Several industry players provide intravenous contrast agents in the market. For instance, VISIPAQUE 320 by GE Healthcare Canada, Inc. is administered intravenously to aid in medical imaging procedures.
The rectal route segment is expected to grow significantly during the forecast period. Contrast agents can also be effectively administered rectally to evaluate conditions such as cancer, ulcerative colitis, or Crohn’s disease. This diagnostic approach involves using contrast media, such as barium sulfate, which is introduced into the lower gastrointestinal tract through an enema administered rectally. The primary goal is to augment the clarity and precision of CT imaging, specifically targeting the lower gastrointestinal tract, encompassing both the colon & rectum.
The neurological disorders segment held the largest share of 28.8% in 2023.The diagnostic assessment of the Central Nervous System (CNS) for neurological disorders drives the uptake of MRI contrast agents, which offer superior imaging of neural structures compared to CT scans. Gadolinium-based Contrast Agents (GBCAs) are employed in MRI procedures to enhance image clarity, thereby improving diagnostic precision by highlighting blood vessels, inflammation, and tumors. Certain GBCAs, such as Prohance, are approved for intravenous administration in adults and pediatric patients aged 2 and above to visualize lesions with abnormal vascularity in the brain, spine, and related tissues. Due to these advantageous properties, the adoption of GBCAs is anticipated to rise. In addition, X-ray and CT contrast agents are widely used to diagnose neurological disorders, further bolstering growth in this segment.
The cardiovascular disorders (CVD) segment is expected to grow at the fastest CAGR during the forecast period. Contrast-enhanced ultrasound imaging, specifically echocardiography, is widely used for cardiovascular system imaging in adult and pediatric patients. Canada offers several contrast agents tailored for diagnosing CVDs. For instance, Definity, an ultrasound-enhancing agent, is approved for improving imaging of cardiac structures such as endocardial borders and ventricular chambers, particularly in cases where standard echocardiograms are inadequate. This enhances the diagnostic accuracy of cardiovascular disorders. In addition, GE Healthcare's VISIPAQUE 320 is designed for angiocardiography, including procedures like aortic root injections, left ventriculography, and selective coronary arteriography. It aids in diagnosing coronary artery conditions and assessing the function of the heart's chambers and valves. The availability of these specialized contrast media products is expected to drive growth in the cardiovascular imaging segment in the coming years.
The hospitals segment held the largest share of 66.0% in 2023 due to the rise in admissions of patients suffering from chronic disorders. The increasing number of MRIs and CTs performed in hospitals and the growing inclination of hospitals toward digitization and automation of radiology patient workflow are anticipated to boost segment growth. According to the Canadian Medical Imaging Inventory Service Report released in August 2022, more than 90% of CT and MRI services are provided within publicly funded healthcare facilities.
The private clinics segment is expected to grow at the fastest CAGR during the forecast period. As per the Canadian Medical Imaging Inventory Service Report issued in August 2022, approximately 10% of MRI and CT services are conducted in privately operated imaging clinics across Canada. The increasing presence of private clinics, an aging population, and extended wait times for imaging services are expected to bolster segment expansion in the foreseeable future.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Canada contrast media market
Modality
Product
Application
Route of Administration
End Use
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Modality
1.2.2. Product
1.2.3. Route of Administration
1.2.4. Application
1.2.5. End Use
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Modality outlook
2.2.2. Product outlook
2.2.3. Route of Administration outlook
2.2.4. Application outlook
2.2.5. End Use outlook
2.3. Competitive Insights
Chapter 3. Canada Contrast Media Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Canada Contrast Media Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Canada Contrast Media Market: Modality Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Canada Contrast Media Market: Modality Movement Analysis
4.3. Canada Contrast Media Market by Modality Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.5. Ultrasound
4.5.1. Ultrasound Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Magnetic Resonance Imaging
4.6.1. Magnetic Resonance Imaging Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. X-ray/Computed Tomography
4.7.1. X-ray/Computed Tomography Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Canada Contrast Media Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Canada Contrast Media Market: Product Movement Analysis
5.3. Canada Contrast Media Market by Product Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Microbubble
5.5.1. Microbubble Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Gadolinium-Based
5.6.1. Gadolinium-Based Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Iodinated
5.7.1. Iodinated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7.2. Iodixanol
5.7.2.1. Iodixanol Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7.3. Iohexol
5.7.3.1. Iohexol Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7.3.2. Iopamidol
5.7.3.2.1. Iopamidol Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7.3.3. Others
5.7.3.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Barium-Based
5.8.1. Barium-Based Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Canada Contrast Media Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Canada Contrast Media Market: Application Movement Analysis
6.3. Canada Contrast Media Market by Application Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Cardiovascular Disorders
6.5.1. Cardiovascular Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Neurological Disorders
6.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Gastrointestinal Disorders
6.7.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Cancer
6.8.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Nephrological Disorders
6.9.1. Nephrological Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Musculoskeletal Disorders
6.10.1. Musculoskeletal Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Others
6.11.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Canada Contrast Media Market: Route of Administration Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Canada Contrast Media Market: Route of Administration Movement Analysis
7.3. Canada Contrast Media Market by Route of Administration Outlook (USD Million)
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
7.5. Intravenous
7.5.1. Intravenous Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Oral Route
7.6.1. Oral Route Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Rectal Route
7.7.1. Rectal Route Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Canada Contrast Media Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Canada Contrast Media Market: End Use Movement Analysis
8.3. Canada Contrast Media Market by End Use Outlook (USD Million)
8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
8.5. Hospitals
8.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Private Clinics
8.6.1. Private Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Others
8.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.2. Key Company Profiles
9.2.1. Voyageur Pharmaceuticals, Ltd
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Bayer AG
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. Bracco
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. GE HealthCare
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Guerbet
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Lantheus Medical Imaging, Inc.
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Grupo Juste
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives